March 22, 2016 / 10:43 AM / in 2 years

BRIEF-Prometic Life Sciences confirms PBI-4050's positive effects on novel biomarkers in patients suffering from metabolic syndrome and Type 2 diabetes

March 22 (Reuters) - Prometic Life Sciences Inc

* Confirms PBI-4050’s positive effects on novel biomarkers in patients suffering from metabolic syndrome and Type 2 diabetes

* Statistically significant decrease in novel biomarkers associated with a high risk of cardiovascular events

* Results further support PBI-4050’s pharmacological activity and clinical benefits in patients

* PBI-4050 has demonstrated a “very good” safety and tolerability profile, with no drug-related serious adverse events Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below